Xenon Pharmaceuticals Inc (XP0.SG)
| Previous Close | 39.80 |
| Open | 40.00 |
| Bid | 39.60 x 0 |
| Ask | 40.40 x 0 |
| Day's Range | 39.80 - 40.00 |
| 52 Week Range | 25.80 - 46.00 |
| Volume | |
| Avg. Volume | 2 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | May 09, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ZacksWhat Makes Xenon Pharmaceuticals (XENE) a New Buy Stock
Xenon Pharmaceuticals (XENE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
GlobeNewswireXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update
VANCOUVER, British Columbia, May 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced it will report its first quarter 2024 financial and operating results after the close of U.S. financial markets on Thursday, May 9, 2024. Conference Call/Webcast Information: Date:Thursday, May 9, 2024 Time:4:30 pm Eastern Time (1:30 pm Pacific Time) Webcast:Pre-register here Dial-In: (800) 715-9871 toll-free, or (646) 307-1963
- GlobeNewswire
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced two oral presentations highlighting XEN1101 clinical data at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver, CO. Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “We are excited that our abstracts focused on XEN1101, including interim data from the ongoing X-TOLE open-label extension st
